Ads
related to: octreotide for carcinoid tumor treatment guidelines- GIST Resistance
Learn more about the complexity of
GIST and a treatment option.
- Dosing Information
Learn more about dosing
information for your patients.
- Access Assistance
Find services and solutions to help
get your patients started faster.
- Patient Education
A patient and care partners guide
with treatment information.
- Physician Information
Download the brochure with
clinical data.
- Request Educational Info
Request patient educational
materials and more.
- GIST Resistance
Search results
Results From The WOW.Com Content Network
An octreotide scan is a type of SPECT scintigraphy used to find carcinoid, pancreatic neuroendocrine tumors, and to localize sarcoidosis. It is also called somatostatin receptor scintigraphy (SRS). Octreotide , a drug similar to somatostatin , is radiolabeled with indium-111 , [ 1 ] and is injected into a vein and travels through the bloodstream.
Octreotide is used for the treatment of growth hormone producing tumors (acromegaly and gigantism), when surgery is contraindicated, pituitary tumors that secrete thyroid-stimulating hormone (thyrotropinoma), [citation needed] diarrhea and flushing episodes associated with carcinoid syndrome, and diarrhea in people with vasoactive intestinal peptide-secreting tumors ().
Introduction of a tyrosine into the 3rd position of the Octreotide sequence resulted in Tyr3-Octreotide (TOC, C), which allows for iodination of the tyrosine residue with the γ-emitter 123 I and subsequent somatostatin receptor targeted imaging. For the use in PRRT TOC was coupled with the chelator DOTA, to form the octapeptide DOTA-TOC (D).
Enterochromaffin cells, which give rise to carcinoid tumors, were identified in 1897 by Nikolai Kulchitsky and their secretion of serotonin was established in 1953 [105] when the "flushing" effect of serotonin had become clinically recognized. Carcinoid heart disease was identified in 1952, and carcinoid fibrosis in 1961. [105]
Enrolled participants had tumors which could not be surgically removed and were worsening while receiving treatment with octreotide. [15] Participants were randomly assigned to receive either 177 Lu dotatate with long-acting octreotide or long-acting octreotide, at a higher dose, alone.
[25] [26] The safety and effectiveness of everolimus in carcinoid tumors have not been established. [25] [26] sunitinib (Sutent) is labeled for treatment of progressive, well-differentiated pancreatic neuroendocrine tumors in patients with unresectable locally advanced or metastatic disease.
Ad
related to: octreotide for carcinoid tumor treatment guidelines